03:51 PM EDT, 10/22/2024 (MT Newswires) -- Amgen ( AMGN ) will launch a biosimilar version of Regeneron's (REGN) Eylea after a US appeals court gave a decision in its favor on Tuesday, Reuters reported citing Amgen's ( AMGN ) spokesperson.

The US Court of Appeals for the Federal Circuit denied Regeneron's request to hold the launch of the biosimilar temporarily during appeal for a related patent dispute decision in West Virginia, according to the report.

Neither Amgen ( AMGN ) nor Regeneron immediately responded to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 320.58, Change: +3.84, Percent Change: +1.21